- Global cannabidiol market expected to increase almost sixfold by 2025
- CNSC offers powerful line of CBD products under Xceptol brand
- CannAssist has forecast first-year sales of $5 million, with steady sales growth moving forward
With industry experts predicting the stabilization of hemp prices and a more predictable market in 2021 (https://ibn.fm/q7JzX), CannAssist International (OTCQB: CNSC) appears to be ideally situated in a sector forecast for remarkable growth. Owner of Xceptor Labs, CannAssist is a biotechnological pharmaceutical and wellness company that markets a powerful line of cannabidiol (“CBD”) products under the Xceptol brand.
“The hemp market’s volatility appears to be coming to an end with stabilization of hemp prices at the end of 2020,” reported a recent article titled “Greater CBD Market Stability Likely in 2021.” The Hemp Grower article continued, “Adam Koh, Hemp Benchmarks’ editorial director, tells Hemp Grower that after 12–18 months of hemp biomass prices declining, they began to stabilize this past October and even increase slightly in November. This likely foretells a more predictable market in 2021, Koh says.”
That stability, combined with projected growth of the global cannabidiol market, which was valued at $4.6 billion in 2019 and is expected to increase almost sixfold by 2025 (https://ibn.fm/cA61X), creates incredible potential for CannAssist. One of the first U.S.-based CBD companies to have its securities listed for trading on a U.S. public capital market, CannAssist is focused on offering high-quality, high-performance brands, and has several products currently under development. Based on growing revenue from raw material and retail sales and expanding social media output and the engagement of strategic partners to help CannAssist ‘get the word out’ and growing distribution arrangements in the US and globally, licensing agreements, retail sales and the Xceptol brand’s international distribution, CannAssist has forecast first-year sales of $5 million, with steady sales growth moving forward.
The company’s products are formulated using Xceptor Labs’ exclusive technology, CiBiDinol, and a proprietary process developed by CannAssist founder Mark Palumbo. The approach addresses vital issues with oil-soluble CBD molecules including delivery, bioavailability and short shelf-life. CannAssist notes that CiBiDinol delivers CBD in a format that is more aligned with the body’s natural bioactivity, combining CBD molecules with penetration-enhancing cyclodextrin. The technology enhances CBD stability and absorption through the skin and gut.
Launched in September 2020, CannAssist’s current Xceptol product lineup includes FDA registered topical pain-cream products formulated using its proprietary CiBiDinol technology. CannAssist is eyeing potential expansion into global markets, including all of North America, Central America, South America, South Africa, the EU, the UK and the Philippines. With that expansion in mind, the company is committed to adding to its strategic manufacturing, laboratory and distribution partners establishing strategic partnerships in ingredient sourcing, manufacturing, processing, laboratory, distribution and public relations and legal representation.
Established in May 2017, CannAssist is headquartered in San Diego County, California, and markets its B2B custom and CiBiDinol raw material technology and its consumer line of cannabidiol (“CBD”) products under the Xceptol brand.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC